Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy - Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, McLaughlin PW, DeBiose DA, Hussey DH, Wahl RL, Division of Radiation Oncology, University of Cincinnati, OH. J Clin Oncol 2003;21:1715-1721

Author： Urologic Oncology Seminars and Original Investigations  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.6, 2003-11, pp. : 486-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 - Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413, University of California-San Francisco, San Francisco, CA. J Clin Oncol 2003;21:1904-1911

By Smith J.A.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 482-482

Elsevier

Access to resources Recommend Favorite

Role of surgeon volume in radical prostatectomy outcomes - Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS, Departments of Urology and Health Services, University of California, Los Angeles, David Geffen School of Medicine and School of Public Health, Los Angeles, CA. J Clin Oncol 2003:21:401-405

By Smith J.A.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 480-480

Elsevier

Access to resources Recommend Favorite

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy - D'Aimco AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M-H, Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA. J Natl Cancer Inst 2003;95:1376-1383

By Chatta G.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 487-488

Elsevier

Access to resources Recommend Favorite

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA - J Clin Oncol 2002;20:2017-2024

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 412-413

Elsevier

Access to resources Recommend Favorite

Erratum to: Successful long-term remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic non-seminomatous germ cell tumor: an additional report to Int J Clin Oncol 2007; 12:485–487

By Takeshita Hideki   Yonese Junji   Fukui Iwao  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 530-530

Springer Publishing Company

Access to resources Recommend Favorite